Speech-Language Pathologists in Lakewood, CA Accepting Medicare

7 Speech-Language Pathologists found. Showing 1 - 7

Mrs. Lynn T Mcinally, SPEECH LANGUAGE PATH Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 5534 Del Amo Blvd, Lakewood, CA 90713 Phone: 562-496-3699

Maranina Mary Eister Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 11647 206th St, Lakewood, CA 90715 Phone: 562-446-7746

Trisha Thapar, MS., CCC-SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 5632 Hazelbrook Ave, Lakewood, CA 90712 Phone: 714-335-4931

Cynthia Meggers, M.S. CCC-SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 6038 Eckleson St, Lakewood, CA 90713 Phone: 562-595-2053

Ms. Yung Han Chen Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 12541 Centralia St, Apt 21, Lakewood, CA 90715 Phone: 352-870-2026

Diana Fitch Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 11507 Massinger St, Lakewood, CA 90715 Phone: 562-924-2856

Phyllis Antoinette Kenworthy, M.A.CCC/SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 3700 South St, Lakewood, CA 90712 Phone: 562-272-6497

News Archive

Researchers discover peacekeeper-immune cells in outer layers of human skin

There are more bacteria living on our skin and in our gut than cells in our body. We need them. But until now no-one knew how the immune system could tell that these bacteria are harmless.

Lack of early market research spending lowers drug success rates

Pharmaceutical market research spending during Launch exceeds all market research spending from Pre-Clinical to Phase III, according to a new industry report by Cutting Edge Information. This lack of early market research spending dramatically reduces a product's viability in the competitive marketplace.

Takeda announces positive Phase 3 ALTA-1L data in first-line therapy for advanced ALK+ NSCLC

Takeda Pharmaceutical Company Limited today announced that intracranial efficacy data from the Phase 3 ALTA-1L (ALK in Lung Cancer Trial of BrigAtinib in 1st Line) trial showed improved intracranial progression-free survival (PFS) and intracranial objective response rate (ORR) with ALUNBRIG (brigatinib) compared to crizotinib among anaplastic lymphoma kinase-positive (ALK+) non-small cell lung cancer (NSCLC) patients.

Big Data and ICT pose serious challenge in disasters but hold promise for effective response

In a recent review article published in the journal Disaster Medicine and Public Health Preparedness, a group of Johns Hopkins' authors evaluated 113 studies using predetermined criteria with the final search taking place on May 1, 2017.

Read more Medical News

› Verified 8 days ago